The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Biopharma Expected to Bring 'Two First-in-Class Antibiotics to Market in 2019'

Research Report
  ()
The likely timelines for approval and commercialization of each drug are discussed in an H.C. Wainwright report. read more >
News Update

Antibody Therapeutics Developer to Present at March Alzheimer's/Parkinson's Conference

News Update
  ()
The biotech was selected to discuss its antibodies that selectively target toxic forms of alpha-synuclein. read more >

Health Tech Firm Completes Enrollment for Female Sexual Function Trial

Research Report
  ()
A Ladenburg Thalmann report reviewed the study design and purpose. read more >

Analyst: Biotech to Have 'Eventful Year' with Data Readouts in Three Indications

Research Report
  ()
This California company expects results from clinical trials in liver disease and psoriasis in 2019. read more >

Large US Market Now Open to Livestock Feed Antibiotic Replacement

  ()
Proprietary OxC-beta livestock feed supplement can supplant the need for maintenance antibiotics. read more >

Coverage Initiated on Cancer Vaccine Firm

Research Report
  ()
An H.C. Wainwright & Co. report explained the reasons for its "bullish view" on this California-based life sciences company. read more >

Coverage Initiated on Producer of Hemp-Derived Cannabidiol Products

Research Report
  ()
A ROTH Capital Partners report presented the reasons for investing in this company. read more >

U.S. Biotech Makes 'The Acquisition We Were Waiting For'

Research Report
  ()
By tucking in this retinal gene therapy firm, the Massachusetts-based company gains assets and synergy. read more >

After Financing Close, Biotech's Subsidiary to Operate Independently

Research Report
  ()
An H.C. Wainwright & Co. report explained the purpose of the funding and how any resulting developments would positively impact the former parent company. read more >

Biotech to Launch Preclinical Studies of Antibody in Eight Cancer Types

Research Report
  ()
This company's new trials, preferred dosing and upcoming biologics license application submission are discussed in an H.C. Wainwright & Co. report. read more >

FDA Grants Breakthrough Status to Biopharma's Lead Candidate for Liver Disease

Research Report
  ()
The California firm's most advanced asset is advancing through Phase 2b, according to a ROTH Capital Partners report. read more >

Biopharma's Foundation Provides for Downside Protection, Upside Realization

Research Report
  ()
An H.C. Wainwright & Co. report described this Israeli firm's solid revenue picture and addressed the undervaluation of a key therapeutic candidate. read more >
News Update

Biotech Identifies Antibody Drug Candidates to Target Toxic Protein Implicated in Parkinson's Disease

News Update
  ()
The Canadian company continues seeking partners to leverage its discovery and development platform. read more >

Clinical Movement Expected in 2019 on Pharma Firm's 'Gene Therapy Promise'

Research Report
  ()
A number of data readouts are expected in the coming months, which could derisk and accelerate development programs, according to an H.C. Wainwright & Co. report. read more >

Report Highlights Biopharma's Breakthroughs on Treatment of Life-Threatening Pediatric Liver Diseases

Research Report
  ()
Analyst expects "transformational year" for company with a phase 3 trial underway. read more >

Biopharma's Drug Well Tolerated in Opioid Withdrawal Study

Research Report
  ()
An H.C. Wainwright & Co. discussed these proof-of-concept data and described the company's planned Phase 1 study. read more >

Accelerated Approval Could Be 'Game Changer' for Biotech

Research Report
  ()
This Canadian company's immunotherapeutic targeting ovarian cancer could advance to market sooner, according to a Mackie Research Capital Corp. note. read more >
News Update

Biotech Offers Reason for Others' Failed Trials of Potential Alzheimer's Disease Treatments

News Update
  ()
This Canadian developer of therapeutics for neurodegenerative diseases bases its opinion, in part, on its own preclinical findings. read more >

Coverage Initiated on Developer of Therapies for Gastrointestinal Disorders

Research Report
  ()
A ROTH Capital Partners report discussed this U.S.-based biopharma's two assets. read more >

Specialty Pharma 'Advances Pipeline' Ahead of Commercializing Lead Skin Therapy

Research Report
  ()
LifeSci Capital reviewed the key takeaways from this Israeli firm's day-long research and development presentation. read more >

Lessons from January…This Could Make You Money Someday

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research does a deep dive into his portfolio to discern trends and lessons to be learned. read more >

Anixa Doesn't Disappoint

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research explains why he has designated this company his 2019 stock of the year. read more >

Early Data for Biotech's Pain Drug Candidate 'Show Promise'

Research Report
  ()
An H.C. Wainwright & Co. report reviewed Phase 1b data for this nonopioid medication being developed for patients with severe pain. read more >

Analyst: Reaction to Trial Data 'Unwarranted'

Research Report
  ()
An analyst's note reviewed the recently announced study results in pancreatic cancer as well as the subsequent decline in stock price. read more >

Analyst Shares 'Revelations from a Pooled Safety Analysis' of Pain Drug

Research Report
  ()
An H.C. Wainwright & Co. report discussed the analgesic's safety profile and how it compares to an on-the-market competitor. read more >
Showing Results: 1 to 25 of 73 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts